Coronado Gloria D, Vollmer William M, Petrik Amanda, Taplin Stephen H, Burdick Timothy E, Meenan Richard T, Green Beverly B
The Center for Health Research, Kaiser Permanente Northwest, 3800 N. Interstate Avenue, Portland, OR 97227, USA.
National Cancer Institute, Process of Care Research Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, 9609 Medical Center Drive, Bethesda, MD 20892-9760, USA.
Contemp Clin Trials. 2014 Jul;38(2):344-9. doi: 10.1016/j.cct.2014.06.006. Epub 2014 Jun 14.
Colorectal cancer is the second-leading cause of cancer deaths in the United States. The Strategies and Opportunities to Stop Colorectal Cancer (STOP CRC) in Priority Populations study is a pragmatic trial and a collaboration between two research institutions and a network of more than 200 safety net clinics. The study will assess the effectiveness of a system-based intervention designed to improve the rates of colorectal-cancer screening using fecal immunochemical testing (FIT) in federally qualified health centers in Oregon and Northern California.
STOP CRC is a cluster-randomized comparative-effectiveness pragmatic trial enrolling 26 clinics. Clinics will be randomized to one of two arms. Clinics in the intervention arm (1) will use an automated, data-driven, electronic health record-embedded program to identify patients due for colorectal screening and mail FIT kits (with pictographic instructions) to them; (2) will conduct an improvement process (e.g. Plan-Do-Study-Act) to enhance the adoption, reach, and effectiveness of the program. Clinics in the control arm will provide opportunistic colorectal-cancer screening to patients at clinic visits. The primary outcomes are: proportion of age- and screening-eligible patients completing a FIT within 12months; and cost, cost-effectiveness, and return on investment of the intervention.
This large-scale pragmatic trial will leverage electronic health record information and existing clinic staff to enroll a broad range of patients, including many with historically low colorectal-cancer screening rates. If successful, the program will provide a model for a cost-effective and scalable method to raise colorectal-cancer screening rates.
结直肠癌是美国癌症死亡的第二大原因。“优先人群中阻止结直肠癌(STOP CRC)”研究是一项务实试验,由两个研究机构与一个由200多家安全网诊所组成的网络合作开展。该研究将评估一种基于系统的干预措施的有效性,该措施旨在提高俄勒冈州和北加利福尼亚州联邦合格健康中心使用粪便免疫化学检测(FIT)进行结直肠癌筛查的比例。
“STOP CRC”是一项整群随机对照有效性务实试验,纳入26家诊所。诊所将被随机分为两组。干预组的诊所将:(1)使用一个自动化、数据驱动且嵌入电子健康记录的程序来识别应进行结直肠癌筛查的患者,并向他们邮寄FIT检测试剂盒(附图片说明);(2)开展一个改进过程(如计划-实施-研究-改进),以提高该项目的采用率、覆盖范围和有效性。对照组的诊所将在患者就诊时为其提供机会性结直肠癌筛查。主要结局包括:年龄符合且有筛查指征的患者在12个月内完成FIT检测的比例;以及干预措施的成本、成本效益和投资回报率。
这项大规模务实试验将利用电子健康记录信息和现有的诊所工作人员,纳入广泛的患者群体,包括许多历史上结直肠癌筛查率较低的患者。如果成功,该项目将为提高结直肠癌筛查率提供一种具有成本效益且可扩展的方法的范例。